Stem definition | Drug id | CAS RN |
---|---|---|
gonadotropin-releasing-hormone (GnRH) inhibitors, peptides | 1279 | 124904-93-4 |
Dose | Unit | Route |
---|---|---|
0.25 | mg | P |
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 0.21 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.63 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.18 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 9.09 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
May 16, 2000 | EMA | N.V. ORGANON | |
July 29, 1999 | FDA | ORGANON USA INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Ovarian hyperstimulation syndrome | 3203.54 | 61.37 | 452 | 1913 | 3212 | 56286490 |
Ascites | 638.09 | 61.37 | 171 | 2194 | 37373 | 56252329 |
Inappropriate schedule of product administration | 178.19 | 61.37 | 81 | 2284 | 83306 | 56206396 |
Ovarian haemorrhage | 162.35 | 61.37 | 25 | 2340 | 308 | 56289394 |
Ovarian enlargement | 138.70 | 61.37 | 23 | 2342 | 464 | 56289238 |
Haemoperitoneum | 138.42 | 61.37 | 30 | 2335 | 2600 | 56287102 |
Abdominal distension | 87.48 | 61.37 | 49 | 2316 | 77577 | 56212125 |
Maternal exposure before pregnancy | 87.13 | 61.37 | 25 | 2340 | 6798 | 56282904 |
Pleural effusion | 83.08 | 61.37 | 49 | 2316 | 85431 | 56204271 |
Adnexal torsion | 80.71 | 61.37 | 14 | 2351 | 372 | 56289330 |
No adverse event | 73.23 | 61.37 | 34 | 2331 | 36340 | 56253362 |
Pelvic fluid collection | 69.83 | 61.37 | 14 | 2351 | 827 | 56288875 |
Needle issue | 68.52 | 61.37 | 22 | 2343 | 8716 | 56280986 |
Haemoconcentration | 67.88 | 61.37 | 10 | 2355 | 89 | 56289613 |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Ovarian hyperstimulation syndrome | 2987.25 | 72.72 | 391 | 1323 | 2849 | 70923881 |
Ascites | 611.04 | 72.72 | 166 | 1548 | 67381 | 70859349 |
Ovarian haemorrhage | 169.60 | 72.72 | 24 | 1690 | 290 | 70926440 |
Ovarian enlargement | 158.34 | 72.72 | 23 | 1691 | 338 | 70926392 |
Haemoperitoneum | 119.30 | 72.72 | 26 | 1688 | 4045 | 70922685 |
Adnexal torsion | 91.17 | 72.72 | 14 | 1700 | 304 | 70926426 |
Pleural effusion | 88.37 | 72.72 | 49 | 1665 | 132815 | 70793915 |
Pelvic fluid collection | 79.43 | 72.72 | 14 | 1700 | 722 | 70926008 |
None
Source | Code | Description |
---|---|---|
ATC | H01CC01 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES HYPOTHALAMIC HORMONES Anti-gonadotropin-releasing hormones |
FDA PE | N0000008638 | Decreased GnRH Secretion |
FDA MoA | N0000175084 | Gonadotropin Releasing Hormone Receptor Antagonists |
MeSH PA | D006727 | Hormone Antagonists |
FDA EPC | N0000175839 | Gonadotropin Releasing Hormone Receptor Antagonist |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Ovulation induction | indication | 61285001 | |
Prevention of Luteinizing Hormone Surge when undergoing Controlled Ovarian Hyperstimulation | indication | ||
Pregnancy, function | contraindication | 289908002 | |
Breastfeeding (mother) | contraindication | 413712001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.65 | acidic |
pKa2 | 12.09 | acidic |
pKa3 | 12.73 | acidic |
pKa4 | 13.33 | acidic |
pKa5 | 13.33 | acidic |
pKa6 | 13.78 | acidic |
pKa7 | 8.8 | Basic |
pKa8 | 8.2 | Basic |
pKa9 | 5.35 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Gonadotropin-releasing hormone receptor | GPCR | ANTAGONIST | CHEMBL | CHEMBL |
ID | Source |
---|---|
4021229 | VUID |
N0000148673 | NUI |
D04302 | KEGG_DRUG |
4021229 | VANDF |
4021230 | VANDF |
C0073629 | UMLSCUI |
CHEBI:135910 | CHEBI |
CHEMBL1251 | ChEMBL_ID |
DB06785 | DRUGBANK_ID |
C061018 | MESH_SUPPLEMENTAL_RECORD_UI |
3877 | IUPHAR_LIGAND_ID |
6830 | INN_ID |
129311-55-3 | SECONDARY_CAS_RN |
IX503L9WN0 | UNII |
16130957 | PUBCHEM_CID |
259264 | RXNORM |
67714 | MMSL |
8280 | MMSL |
d04447 | MMSL |
008055 | NDDF |
008056 | NDDF |
116102008 | SNOMEDCT_US |
326088005 | SNOMEDCT_US |
395728002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Ganirelix Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0052-0301 | INJECTION, SOLUTION | 250 ug | SUBCUTANEOUS | NDA | 23 sections |
Ganirelix Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0548-5001 | INJECTION | 250 ug | SUBCUTANEOUS | ANDA | 23 sections |
Ganirelix Acetate | Human Prescription Drug Label | 1 | 55566-1000 | INJECTION, SOLUTION | 250 ug | SUBCUTANEOUS | ANDA | 19 sections |
Fyremadel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55566-1010 | INJECTION, SOLUTION | 250 ug | SUBCUTANEOUS | ANDA | 23 sections |
Fyremadel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55566-1010 | INJECTION, SOLUTION | 250 ug | SUBCUTANEOUS | ANDA | 23 sections |
Ganirelix Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-554 | INJECTION, SOLUTION | 250 ug | SUBCUTANEOUS | ANDA | 23 sections |
Ganirelix Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 78206-138 | INJECTION, SOLUTION | 250 ug | SUBCUTANEOUS | NDA | 23 sections |
Ganirelix Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 78206-138 | INJECTION, SOLUTION | 250 ug | SUBCUTANEOUS | NDA | 23 sections |